{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T08:59:38Z","timestamp":1761469178356,"version":"build-2065373602"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,10,26]]},"DOI":"10.7759\/cureus.95422","type":"journal-article","created":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T08:56:11Z","timestamp":1761468971000},"source":"Crossref","is-referenced-by-count":0,"title":["Comparative Efficacy of Ublitixumab Versus Natalizumab in the Treatment of Relapsing and Remitting Multiple Sclerosis"],"prefix":"10.7759","author":[{"given":"Sai V","family":"Chitturi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonnalagadda","family":"Amith Priyansu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akhil","family":"Sadhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hemanthi","family":"Ramisetty","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manoj R","family":"Pallapothu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deepiikha","family":"Kogantii","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph17176397","article-title":"Effect of a combined program of strength and dual cognitive-motor tasks in multiple sclerosis subjects","volume":"17","author":"Guti\u00e9rrez-Cruz C","year":"2020","unstructured":"Guti\u00e9rrez-Cruz C, Rojas-Ruiz FJ, De la Cruz-M\u00e1rquez JC, Guti\u00e9rrez-D\u00e1vila M. Effect of a combined program of strength and dual cognitive-motor tasks in multiple sclerosis subjects. Int J Environ Res Public Health. 2020, 17:6397. 10.3390\/ijerph17176397","journal-title":"Int J Environ Res Public Health"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011381.pub3","article-title":"Immunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: a network meta-analysis","volume":"1","author":"Gonzalez-Lorenzo M","year":"2024","unstructured":"Gonzalez-Lorenzo M, Ridley B, Minozzi S, et al.. Immunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: a network meta-analysis. Cochrane Database Syst Rev. 2024, 1:CD011381. 10.1002\/14651858.CD011381.pub3","journal-title":"Cochrane Database Syst Rev"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD013247.pub2","article-title":"Ocrelizumab for multiple sclerosis","volume":"5","author":"Lin M","year":"2022","unstructured":"Lin M, Zhang J, Zhang Y, Luo J, Shi S. Ocrelizumab for multiple sclerosis. Cochrane Database Syst Rev. 2022, 5:CD013247. 10.1002\/14651858.CD013247.pub2","journal-title":"Cochrane Database Syst Rev"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.78.7390","article-title":"Deleting malignant B cells with second-generation anti-CD20 antibodies","volume":"36","author":"Sopp J","year":"2018","unstructured":"Sopp J, Cragg MS. Deleting malignant B cells with second-generation anti-CD20 antibodies. J Clin Oncol. 2018, 36:2323-5. 10.1200\/JCO.2018.78.7390","journal-title":"J Clin Oncol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-008-6001-2","article-title":"Pathophysiology of multiple sclerosis","volume":"255","author":"Korn T","year":"2008","unstructured":"Korn T. Pathophysiology of multiple sclerosis. J Neurol. 2008, 255:2-6. 10.1007\/s00415-008-6001-2","journal-title":"J Neurol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1002\/eji.200526065","article-title":"Reduced suppressive effect of CD4+CD25high regulatory T cells on the T cell immune response against myelin oligodendrocyte glycoprotein in patients with multiple sclerosis","volume":"35","author":"Haas J","year":"2005","unstructured":"Haas J, Hug A, Vieh\u00f6ver A, et al.. Reduced suppressive effect of CD4+CD25high regulatory T cells on the T cell immune response against myelin oligodendrocyte glycoprotein in patients with multiple sclerosis. Eur J Immunol. 2005, 35:3343-52. 10.1002\/eji.200526065","journal-title":"Eur J Immunol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000037297","article-title":"Review of multiple sclerosis: epidemiology, etiology, pathophysiology, and treatment","volume":"103","author":"Haki M","year":"2024","unstructured":"Haki M, Al-Biati HA, Al-Tameemi ZS, Ali IS, Al-Hussaniy HA. Review of multiple sclerosis: epidemiology, etiology, pathophysiology, and treatment. Medicine (Baltimore). 2024, 103:e37297. 10.1097\/MD.0000000000037297","journal-title":"Medicine (Baltimore)"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2006.09.012","article-title":"Interferon beta-1a therapy enhances CD4+ regulatory T-cell function: an ex vivo and in vitro longitudinal study in relapsing-remitting multiple sclerosis","volume":"182","author":"de Andr\u00e9s C","year":"2007","unstructured":"de Andr\u00e9s C, Aristimu\u00f1o C, de Las Heras V, et al.. Interferon beta-1a therapy enhances CD4+ regulatory T-cell function: an ex vivo and in vitro longitudinal study in relapsing-remitting multiple sclerosis. J Neuroimmunol. 2007, 182:204-11. 10.1016\/j.jneuroim.2006.09.012","journal-title":"J Neuroimmunol"},{"key":"ref9","unstructured":"Ciccone, I. Ublituximab reduces relapses compared with teriflunomide in multiple sclerosis. (2022). Accessed. October 4, 2022: https:\/\/www.neurologylive.com\/view\/ublituximab-reduces-relapses-compared-teriflunomide-multiple-sclerosis.."},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1177\/1756285615605429","article-title":"Monoclonal antibody therapies for the treatment of relapsing-remitting multiple sclerosis: differentiating mechanisms and clinical outcomes","volume":"8","author":"Lycke J","year":"2015","unstructured":"Lycke J. Monoclonal antibody therapies for the treatment of relapsing-remitting multiple sclerosis: differentiating mechanisms and clinical outcomes. Ther Adv Neurol Disord. 2015, 8:274-93. 10.1177\/1756285615605429","journal-title":"Ther Adv Neurol Disord"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1177\/1352458520918375","article-title":"A phase 2 multicenter study of ublituximab, a novel glycoengineered anti-CD20 monoclonal antibody, in patients with relapsing forms of multiple sclerosis","volume":"27","author":"Fox E","year":"2021","unstructured":"Fox E, Lovett-Racke AE, Gormley M, et al.. A phase 2 multicenter study of ublituximab, a novel glycoengineered anti-CD20 monoclonal antibody, in patients with relapsing forms of multiple sclerosis. Mult Scler. 2021, 27:420-9. 10.1177\/1352458520918375","journal-title":"Mult Scler"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2024.1479476","article-title":"Comparative efficacy and tolerability of ublituximab vs. other monoclonal antibodies in the treatment of relapsing multiple sclerosis: a systematic review and network meta-analysis of randomized trials","volume":"15","author":"Moloney E","year":"2024","unstructured":"Moloney E, Mashayekhi A, Sharma S, et al.. Comparative efficacy and tolerability of ublituximab vs. other monoclonal antibodies in the treatment of relapsing multiple sclerosis: a systematic review and network meta-analysis of randomized trials. Front Neurol. 2024, 15:1479476. 10.3389\/fneur.2024.1479476","journal-title":"Front Neurol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-024-02011-w","article-title":"Drugs targeting CD20 in multiple sclerosis: pharmacology, efficacy, safety, and tolerability","volume":"84","author":"Carlson AK","year":"2024","unstructured":"Carlson AK, Amin M, Cohen JA. Drugs targeting CD20 in multiple sclerosis: pharmacology, efficacy, safety, and tolerability. Drugs. 2024, 84:285-304. 10.1007\/s40265-024-02011-w","journal-title":"Drugs"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa020696","article-title":"A controlled trial of natalizumab for relapsing multiple sclerosis","volume":"348","author":"Miller DH","year":"2003","unstructured":"Miller DH, Khan OA, Sheremata WA, et al.. A controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2003, 348:15-23. 10.1056\/NEJMoa020696","journal-title":"N Engl J Med"},{"key":"ref15","article-title":"Natalizumab: a new treatment for relapsing remitting multiple sclerosis","volume":"3","author":"Hutchinson M","year":"2022","unstructured":"Hutchinson M. Natalizumab: a new treatment for relapsing remitting multiple sclerosis. Therapeutics and Clinical Risk Management. 2022, 3:259-68.","journal-title":"Therapeutics and Clinical Risk Management"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.2147\/NDT.S114636","article-title":"The use of natalizumab for multiple sclerosis","volume":"13","author":"Brandstadter R","year":"2017","unstructured":"Brandstadter R, Katz Sand I. The use of natalizumab for multiple sclerosis. Neuropsychiatr Dis Treat. 2017, 13:1691-702. 10.2147\/NDT.S114636","journal-title":"Neuropsychiatr Dis Treat"},{"key":"ref17","unstructured":"Meglio M. Natalizumab improves disability in relapsing-remitting multiple sclerosis. (2020). Accessed. July 11, 2020: https:\/\/www.neurologylive.com\/view\/natalizumab-improves-disability-in-relapsingremitting-multiple-sclerosis."}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/380746-comparative-efficacy-of-ublitixumab-versus-natalizumab-in-the-treatment-of-relapsing-and-remitting-multiple-sclerosis","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T08:56:13Z","timestamp":1761468973000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/380746-comparative-efficacy-of-ublitixumab-versus-natalizumab-in-the-treatment-of-relapsing-and-remitting-multiple-sclerosis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,26]]},"references-count":17,"URL":"https:\/\/doi.org\/10.7759\/cureus.95422","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10,26]]}}}